Allergen-specific B-cell receptor and immunoglobulin (BCR/Ig)

Allergen-specific B-cell receptors (BCRs) and their secreted immunoglobulin (Ig) counterparts are the primary mediators of allergic sensitization and clinical reactivity (Galli & Tsai, Nature, 2012). These molecules are characterized by their ability to bind specifically to environmental allergens, such as pollen, dust mites, or food proteins. In allergic individuals, the production of allergen-specific IgE leads to the priming of mast cells and basophils via the high-affinity IgE receptor, FcεRI (NIH/NIAID). Upon re-exposure, the allergen cross-links these IgE molecules, triggering the rapid release of inflammatory mediators responsible for symptoms ranging from hay fever to life-threatening anaphylaxis. Therapeutic interventions target this pathway by neutralizing free IgE, such as with Omalizumab (Genentech/Novartis, 2003), or by depleting IgE-producing B cells through targeting the membrane-bound BCR (Gauvreau et al., JACI, 2014). Additionally, allergen immunotherapy (AIT) aims to induce a class switch toward protective IgG4 antibodies, which act as 'blocking' antibodies to prevent IgE-mediated activation (Akdis & Akdis, Nature Reviews Immunology, 2014). Understanding the dynamics of these receptors is crucial for developing precision medicines that can induce long-term immune tolerance in allergic patients.

Other names

Allergen-specific BCRAllergen-specific IgEAllergen-specific IgGSurface immunoglobulinMembrane-bound immunoglobulinAntigen-specific B-cell receptor

Neutralization of circulating IgE to prevent binding to high-affinity FcεRI receptors, depletion of IgE-switched B cells by targeting the M1-prime segment of membrane-bound BCRs, and induction of allergen-specific IgG4 antibodies that act as competitive blockers (Galli & Tsai, Nature, 2012; Akdis & Akdis, Nature Reviews Immunology, 2014).